Insider Selling: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Sells 22,258 Shares of Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) COO Mary Dibiase sold 22,258 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $10,016.10. Following the sale, the chief operating officer now owns 490,980 shares of the company's stock, valued at approximately $220,941. This represents a 4.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

X4 Pharmaceuticals Stock Performance

Shares of NASDAQ:XFOR traded up $0.01 during midday trading on Monday, hitting $0.49. The company had a trading volume of 2,333,226 shares, compared to its average volume of 2,696,270. The company has a market cap of $83.84 million, a price-to-earnings ratio of -5.46 and a beta of 0.14. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The company has a fifty day moving average of $0.55 and a two-hundred day moving average of $0.61. X4 Pharmaceuticals, Inc. has a 12-month low of $0.26 and a 12-month high of $1.60.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. SG Americas Securities LLC raised its stake in X4 Pharmaceuticals by 233.0% during the 4th quarter. SG Americas Securities LLC now owns 183,152 shares of the company's stock worth $134,000 after acquiring an additional 128,148 shares during the period. Barclays PLC lifted its stake in shares of X4 Pharmaceuticals by 196.0% during the 3rd quarter. Barclays PLC now owns 277,682 shares of the company's stock valued at $185,000 after buying an additional 183,861 shares in the last quarter. XTX Topco Ltd boosted its holdings in X4 Pharmaceuticals by 41.7% in the 3rd quarter. XTX Topco Ltd now owns 157,642 shares of the company's stock worth $106,000 after buying an additional 46,397 shares during the period. Jane Street Group LLC increased its stake in X4 Pharmaceuticals by 103.4% in the 3rd quarter. Jane Street Group LLC now owns 248,447 shares of the company's stock worth $166,000 after buying an additional 126,296 shares in the last quarter. Finally, State Street Corp raised its holdings in X4 Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,952,895 shares of the company's stock valued at $1,976,000 after acquiring an additional 189,105 shares during the period. 72.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on XFOR. Stifel Nicolaus cut their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, November 14th. HC Wainwright restated a "buy" rating and set a $1.50 price target on shares of X4 Pharmaceuticals in a research note on Tuesday, January 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.